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Abstract
The notion that the human adult heart is a quiescent organ incapable of self-regeneration has been successfully challenged. It is now 
evident that the heart possesses a significant ability for repair and regeneration. Stem cells of endogenous cardiac origin are currently con-
sidered to possess the greatest ability to differentiate into cardiomyocytes. The major types of cardiac stem cells that show a promising 
potential to replace damaged cardiomyocytes include C-KIT positive (C-KIT+) cardiac progenitor cells, cardiosphere-derived progenitor cells, 
islet-1 (Isl1+) cardiac progenitor cells, side-population cardiac progenitor cells, epicardium-derived progenitor cells and stem cell antigen-1 
(SCA1+) cardiac progenitor cells. Moreover, stem cells of extra-cardiac origin are also thought to restore contractility and vascularization of 
the myocardium. These include skeletal myoblasts, bone marrow mononuclear cells, mesenchymal stem cells, endothelial progenitor cells 
as well as embryonic stem cells. The need for further investigation on cardiac stem cell therapeutic strategies still remains.
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Introduction
Cardiovascular disease is a leading cause of death worldwide. 
Following an ischaemic event, the myocardium suffers perma-
nent loss of cardiac tissue and gradually deteriorates towards 
heart failure. Over 26 million individuals suffer from congestive 
heart failure worldwide, whilst in Europe alone, approximately 
3.5 million patients are newly diagnosed with this condition on 
a yearly basis.1 The major causative factor behind this cardiac 
pathology lies in the insufficiency of pumping action by the 
cardiomyocytes, or their loss, following the survival of a myo-
cardial infarction (MI). Following MI, local cardiac compensa-
tory mechanisms are activated, which may in turn, give rise to 
a decline in cardiac function, or sudden cardiac death.2
To date, cardiac transplantation is the first-line treatment for 
end-stage heart failure. However, this type of treatment is limi-
ted primarily by the availability of donor hearts, as well as by 
the specific immune response triggered by the introduction of 
foreign tissue. This leaves the recipient with no other choice 
but to be prescribed with life-long immunosuppressive drugs. 
Moreover, the prognosis for end-stage heart failure is not so 
favourable. In fact, only 50% of newly-diagnosed cases survive 
the following year, despite receiving adequate pharmacological 
therapy or an implantation of a mechanical left ventricular as-
sisting device.3
Regeneration/repair of damaged or ischaemic cardiomyocytes 
may be addressed through the use of fully functional and 
self-renewing stem cells that have the ability to form diffe-
rent cell types, and hence, the potential to restore the viability 
or function of defective tissue. As can be seen in Figure 1, 
stem-cell therapy for cardiac dysfunction may be applied either 
through the implantation of stem cells, or their derivatives, 
directly into the heart or else via the activation of endogenous 
cardiac repair mechanisms that have the ability to replace da-
maged cardiomyocytes and promote vascular reconstruction.4-5 
For this reason, the main objective behind this literature review 
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Figure 1. Outline of Stem Cell Therapy for Cardiac Dysfunction
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lies in highlighting the major types of exogenous and endoge-
nous cardiac stem cell lineages that are thought to enhance 
the ability of the myocardium to regenerate or be repaired fo-
llowing significant injury or dysfunction.
Search Strategy and Selection Criteria
A literature search for this review was conducted at the Fa-
culty of Medicine & Surgery Library at the University of Malta 
in February 2015. Most of the literature was obtained online 
from various electronic databases such as PubMed Health®, 
Sage® and Science Direct®. The initial literature search involved 
general keywords such as: ‘stem cell therapy’, ‘myocardium’, 
‘regeneration’, ‘myocardial infarction’, ‘heart failure’ and ‘ma-
nagement’. Shortly after, another literature search was conduc-
ted using specific keywords such as: ‘cardiac stem cells’ and 
‘exogenous stem cells’. Several relevant free access articles 
were sought after and filtered according to relevance, date and 
language of publication. The bibliographies of such publications 
were also searched for potential referencing sources. Whene-
ver possible, primary sources of literature were acquired. The 
final review consisted of 57 different referencing sources, which 
were published in English within the past 24 years, from Octo-
ber 1990 to August 2014.
Stem Cells of Endogenous Cardiac Origin
The heart has traditionally been considered as a post-mitotic 
organ, with no ability to proliferate or self-renew, since matu-
re cardiomyocytes withdraw from the cell cycle. Contradictory 
data to this belief started to accumulate when cardiomyocyte 
proliferation was detected under certain pathological condi-
tions, namely ischaemia and hypertension.6-9 In fact, recent 
data suggests that there are niches within the heart, located 
within the deep tissue of the atria and apex, which contain 
stem cells that are able to divide, and are more likely to diffe-
rentiate into cardiac cells.10-11 The major types of cardiac stem 
cells (CSC) that show a promising potential to replace damaged 
cardiomyocytes are C-KIT positive (C-KIT+) cardiac progenitor 
cells, cardiosphere-derived progenitor cells, islet-1 (Isl1+) car-
diac progenitor cells, side-population cardiac progenitor cells, 
epicardium-derived progenitor cells and stem cell antigen-1 
(SCA1+) cardiac progenitor cells.
C-KIT+ Cardiac Progenitor Cells
Several scientists sought to explore the existence of circulating 
stem cells that are specifically housed in the heart and whether 
these are able to differentiate into cardiac lineages. Most of the 
initial studies that were conducted worldwide focused on cells 
expressing the tyrosine-kinase receptor C-KIT+, a known marker 
of haematopoetic progenitor cells (HPC).
Following MI, C-KIT+ cardiac progenitor cells were found to re-
generate cardiomyocytes when injected into an infarcted tissue 
zone.12 This conclusion was based upon the histological stai-
ning results, whereby 68% of cardiac muscle cells within the in-
farcted tissue were proven to be of exogenous origin and later 
supported by further studies.10,13-15 In addition, throughout the 
past 5 years, this specific type of CSC has accumulated enou-
gh justification for their application in human clinical trials. 
Favourable effects on cardiac repair and myocardial functional 
recovery was reported.16-17
In these clinical trials, autologous C-KIT+ cardiac progenitor 
cells were isolated and expanded ex-vivo from post-MI patients 
undergoing coronary artery bypass grafting (CABG). Subjects 
were randomized to receive either intracoronary infusion of 
C-KIT+ cardiac progenitor cells, or conventional therapy. Preli-
minary findings have demonstrated a significant improvement 
in left ventricular (LV) function as well as a reduction in infarct 
size in the group who have received treatment with C-KIT+ 
cardiac progenitor cells, when compared to the subjects who 
received conventional therapeutic measures.16-17 Despite the 
integrity of the data generated throughout these clinical trials, 
concerns have been raised regarding the processes of patient 
randomization.18 Thus, research pertaining to the full spectrum 
of benefits and downsides of this type of CSC is currently on-
going. 
Cardiosphere-derived Progenitor Cells
The term “cardiosphere” refers to a population of undifferen-
tiated cells that can be isolated via a cardiac biopsy and ob-
tained through enzymatic digestion of explanted cardiac tis-
sue.19 Cardiosphere-derived stem cells (CDC) are characterized 
as a heteregenous cell population, containing a central core 
of C-KIT+ cardiac progenitor cells that have been previously 
discussed.
There are various studies that have established the application 
of CDC as a promising candidate for cardiac stem cell therapy. 
The functional benefits of CDC are their superior potency and 
myocardial repair efficacy compared to other CSC populations.20 
In fact, in addition to C-KIT+ cardiac progenitor cells, CDC pre-
sent an alternative source of accumulating data from human 
clinical trials.
The study involving the cardiosphere-derived autologous stem 
cells to reverse ventricular dysfunction (CADUCEUS) consisted 
of a randomised phase 1 clinical trial, that assessed the safety 
of autologous intracoronary (IC) CDC delivery in post-MI pa-
tients.21 The CDC were obtained via percutaneous endomyocar-
dial biopsies, expanded ex vivo, and delivered by IC injection 
into the infarcted coronary arteries 2 to 4 weeks following MI. 
Magnetic resonance imaging (MRI) at 3 months post IC CDC 
injection denoted a reduction in scar tissue, increased viability 
of heart mass, as well as an increased regional systolic wall 
thickening, when compared to the control group. A statistically 
significant improvement in overall LV function was not obser-
ved. Nevertheless, the preliminary results from this clinical trial 
demonstrated that CDC therapy appears to be safe. Indeed, 
this type of CSC warrants further investigation.
Islet-1 (Isl1+) Cardiac Progenitor Cells
It is known that progenitor cells in the developing heart are 
reliant on cardiac-specific transcription factors for their diffe-
rentiation. Isl1+ is a transcription factor that is expressed in 
early cardiac progenitor cells, until they differentiate. Cardiac 
Isl1+ expression in adults is mainly confined to the sinoatrial 
node.22 Genetic studies have demonstrated that Isl1+ is impor-
tant for survival, proliferation and migration of early cardiac 
progenitors.23-25 In addition, Isl1+ cardiac progenitor cells have 
been suggested to contribute to various cardiac lineages during 
in vitro differentiation studies. In fact, it is thought that cer-
tain cardiac progenitor cells may be multi-potent, however this 
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claim still needs to be demonstrated in vivo.24-27
It has recently been depicted that a population of Isl1+ expres-
sing cells in the human fetal heart may give rise to cardiac 
muscle in the post-natal heart.25 Previous studies have shown 
that these types of stem cells can be maintained in their undi-
fferentiated state during in vitro culture, and were later able to 
differentiate into cardiac muscle as well as smooth muscle.24,26 
Unfortunately, the relative scarcity of Isl1+ cardiac progenitor 
cells in the human adult heart, their largely non-proliferative 
state in the post-natal period and their lack of considerable 
expansion post MI, cast doubt on their application for repair 
and regeneration of the myocardium.25
Side-population Cardiac Progenitor Cells
Side-population cardiac progenitor cells (SP) possess a unique 
ability to efflux a DNA binding dye, namely Hoechst 33342, that 
is conferred by an ATP-binding transporter. In humans, these 
types of transporters are encoded by the ABCG2 gene, which 
can be used as a determinant of the cardiac SP cells during 
flow cytometry.5
There are few studies demonstrating the application of this 
type of CSC in attempting to regenerate the myocardium after 
an ischaemic event. However, it has been suggested that the 
infusion of cardiac SP cells into cryo-injured hearts led to the 
homing of these cells into the infarcted tissue, and resulted 
in differentiation of a proportion of surviving cells into cardiac 
muscle or smooth muscle.28 The combination of cell surface 
marker studies with lineage tracing experiments in the near 
future will provide a more accurate tracking of the SP fate in 
vivo, and as a result, better characterization of their cardiac 
regenerative properties.
Stem Cell Antigen-1 (SCA1+) Cardiac Progenitor Cells
Although the SCA1 gene is not present in humans, there are 
related genes of the LY6 family that are involved in cell ad-
hesion, migration and extracellular matrix (ECM) degradation. 
SCA1+ cardiac progenitor cells were first investigated in the 
adult murine myocardium, and were later classified as a type 
of CSC which lack haemopoeitic lineage markers.29
It is suggested that in combination with oxytocin, the differen-
tiation of SCA1+ cardiac progenitor cells in vitro, may result in 
the formation of spontaneously beating cardiomyocytes.30 This 
statement has been supported by further experimentation.31 
Moreover, it has been shown that cardiomyocytes require stem 
cell antigen-1 to upregulate the secretion of paracrine effectors 
which induce angiogenesis and limit cardiac apoptosis. Thera-
peutically, it is thought that stem-cell antigen-1 may promote 
CSC survival following engraftment into injured cardiac tissue, 
which will in turn influence revascularization and myocardial 
repair.5 However, their potential to form cardiac muscle in the 
elderly population is currently being questioned.
 
Table 1 summarizes the reviewed information about the major 
types of CSC that have gathered significant evidence in favour 
of repair or regeneration of the myocardium following cardiac 
dysfunction.
Stem Cells of Extra-cardiac Origin
Exogenous stem cells (ESC) comprise at least two different 
groups of cells: the bone marrow derived cells and a circulating 
pool of stem cells, which are partly derived from the bone ma-
rrow. The most extensively studied extra-cardiac stem cells to 
date are the bone marrow derived cells. In fact, this type of ESC 
has proceeded to clinical trials in relation to acute and chro-
nic myocardial infarction, as well as dilated cardiomyopathy. 
The major types of stem cells of extra-cardiac origin that show 
promising potential to be applied in cardiac stem cell therapy 
include skeletal myoblasts, bone marrow mononuclear cells, 
mesenchymal stem cells, endothelial progenitor cells as well 
as embryonic stem cells.
Skeletal Myoblasts
Skeletal myoblasts (SKM) can be referred to as progenitor cells 
that are located within the basal lamina of skeletal muscle 
(SM) fibres. Their activation is often a result of injury, which 
is manifested by the mobilization, proliferation, differentiation 
and ultimately the fusion into new muscle fibres.32 This type 
of ESC may be isolated via a SM biopsy and expanded in vitro. 
SKM were amongst the first types of ESC that were utilized 
in clinical trials, particularly in the setting of chronic MI.33 An 
advantage of SKM over other types of ESC is that they are resis-
tant to ischaemia. This factor increases their chance of survival 
following the development of an infarcted scar.34-36
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Stem Cell Type Suggested Origin In Vitro Potency In Vivo Fate Clinical Trials References
C-KIT+ Cardiac progenitors Early cardiogenic mesoderm Multipotency Cardiac muscle, smooth 
muscle & endothelium
Phase-1 Ref 10, 12-17
Cardiosphere-derived 
progenitors
Heteregenous cardiac origin Multipotency Cardiac muscle, smooth 
muscle & endothelium
Phase-1 Ref 20-21
Islet-1 cardiac progenitors Embryonic second heart 
field
Suggested to be multipotent Not applicable None Ref 22, 24-27
Side population cardiac 
progenitors
Neural crest Cardiac muscle Cardiac muscle, smooth 
muscle, endothelium & 
peripheral nervous tissue
None Ref 28
Stem cell antigen-1 cardiac 
progenitors
Poorly defined Cardiac muscle, chondrocytes 
& osteocytes
Cardiac muscle None
The major types of cardiac stem cells that have gathered significant evidence in favour of repair or regeneration of the myocardium following cardiac dys-
function are shown. In comparison with extra-cardiac stem cells, endogenous cardiac stem cells have shown a more promising potential for cardiovascular 
differentiation and a reduced risk of tumour formation. However, these types of cells are thought to undergo senescence and their availability may be less 
prominent in adult tissues.
Table  1. Summary of Endogenous Stem Cell Populations
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The transplantation of SKM has been evaluated clinically in 
attempt to restore cardiac function, particularly as a thera-
peutic intervention for heart failure. Studies with a 4-month 
and 10-month follow-up both demonstrated an increase in left 
ventricular ejection fraction (LVEF) and an overall improvement 
in systolic shortening in SKM-implanted tissue.35,37 Moreover, 
strengthening of the left ventricular wall and a reduction in size 
of the post-infarction scars were observed in enrolled subjects.
Reported adverse effects related to the SKM transplantation 
procedure, include ventricular tachycardia (VT) and atrial fi-
brillation (AF). Although these arrhythmias were detected in a 
short time frame following the intervention, most were well-to-
lerated and resolved clinically.35 The future of such promising 
strategy solely lies in its modification through genetic enginee-
ring, with the aim of potentiating the action of SKM paracrine 
effectors and perfecting their cardiotrophic action.
Bone Marrow Mononuclear Cells
The bone marrow mononuclear subset is heterogenous and 
comprises HPC, mesenchymal stem cells (MSC), as well as en-
dothelial progenitor cells (EPC).38 These types of adult ESC have 
long been considered as an attractive option to be studied in 
light of their application in the promotion of growth of myocar-
dial tissue. Despite the fact that their differentiation potential is 
less compared to embryonic stem cells and HPC comprise less 
than 0.1% of bone marrow mononuclear cell (BMMNC) samples, 
a wave of clinical trials using the latter still took place in the 
past decade.
Approximately 2000 subjects have received BMMNC therapy for 
ischaemic cardiomyopathy, collectively amongst three different 
studies.39-41 Unfortunately, cardiac function improvements in 
these clinical trials were modest. Similarly, in another phase-2 
clinical trial, no significant improvement in LV end-systolic vo-
lume was reported.42 Nonetheless, some scientists believe that 
cardiac cell therapy with BMMNC may prosper in combination 
with growth factors or other proteins that are capable of an-
giogenesis or cardiomyocyte proliferation.4 Thus, attempts to 
achieve favourable cardiac repair post-MI using this type of ESC 
are still underway.
Mesenchymal Stem Cells
MSC represent another group of stem cells that are located in 
the bone-marrow, as well as in other tissues such as umbili-
cal cord blood and adipose tissue. This type of ESC has been 
said to differentiate into cardiomyocytes in the presence of the 
demethylating agent 5-azacytidine or when co-cultured with 
other cardiomyocytes.43-45 Contrastingly, in vitro differentiation 
into functional cardiomyocytes failed.45
The very first clinical trial depicting post-MI treatment with 
MSC infusions took place six years ago. It was reported that a 
significant improvement in LV function occurred three months 
post-injection in enrolled patients.34 Similarly, a more recent 
study demonstrated that MSC possess the ability to reduce in-
farct size and increase contractile improvement.47 On top of 
these benefits, a limited-sample study also reported an increa-
sed perfusion in the infarcted tissue.47
In spite of the fact that favourable findings have been obtai-
ned during multiple clinical trials, some researchers have no-
ted that MSC engraft poorly in cardiac tissue. Thus, theories 
have now shifted to support a mechanism involving paracrine 
mediators that are able to promote angiogenesis, as well as 
adipose-tissue derived stem cells that are thought to promote 
new cardiomyocyte formation.46-49
Endothelial Progenitor Cells
Angiogenesis was initially thought to occur solely through the 
proliferation of mature endothelial cells. However, this belief 
was recently challenged upon the discovery that bone-marrow 
derived stem cells are able to incorporate into the microvas-
culature of prominent injury sites, particularly following MI, 
cancer or burns.50 Similar to skeletal myoblasts, EPC are resis-
tant to ischaemia and thus, are considered to be an intriguing 
concept for cardiac therapeutic intervention.
The initial pre-clinical studies with implanted EPC into infarc-
ted myocardium have resulted in improved LV function and 
inhibited fibrosis.51-52 Small clinical trials have later confirmed 
the improvement of LV function in human cases of both acu-
te and chronic myocardial ischaemia.53 Nonetheless, the major 
concern regarding the application of EPC for cardiac muscle 
regeneration lies in the fact that the circulating pool of EPC is 
reduced in patients with cardiac diseases, and co-morbidities 
such as diabetes mellitus, hypertension or hypercholestero-
laemia.54-55 This issue is very problematic since this type of 
therapy was designed to treat patients with coronary artery 
disease and cardiovascular risk factors. Thereby, more research 
aimed at enhancing the therapeutic benefits in patients with 
cardiovascular disease is required.
Embryonic Stem Cells
Embryonic stem cells can be harvested from the inner cell 
mass of a blastocyst. Under ideal settings, they are able to give 
rise to multiple lines of cells to produce a particular organ or 
tissue; including the growth of new cardiomyocytes. However, 
considerable technical and ethical issues exist with the appli-
cation of this type of ESC in human subjects. 
Primarily, the inadvertent transplantation of undifferentiated 
pluripotent stem cells has been shown to pose significant ris-
ks to the host due to their large tumorigenic potential, when 
compared to other stem cell lineages.5 Moreover, this type of 
ESC is more likely to induce host immune rejection following 
transplantation due to its allogeneity. Thereby, it is necessary 
for these limitations to be fully addressed before the success-
ful application of embryonic stem cells in cardiac muscle rege-
neration. Table 2 summarizes the reviewed information about 
the major types of ESC that have gathered significant evidence 
in favour of repair or regeneration of the myocardium following 
cardiac dysfunction.
Delivery of Transplanted Stem Cells into the Myocardium
A consensus still needs to be found with regards to the optimal 
method of delivery of transplanted stem cells into the myocar-
dium. The most promising methods include IC, intramyocardial 
(IM), or intravenous (IV) routes. The most clinically practiced 
form of stem cell delivery is, by far, the IC approach. This pro-
cedure is usually carried out simultaneously during a percu-
taneous coronary intervention following an MI, where a direct 
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administration of stem cells is delivered into the myocardium 
via the coronary arteries. Whilst it is considered as safe and 
efficient, this method fails to deliver stem cells to myocardial 
sites of interest that are poorly perfused.56
The possibility of using IV injections to deliver stem cells into 
the myocardium is thought to be highly inefficient, albeit inex-
pensive and a minimally invasive option. Thus, it is currently 
being investigated for use only in patients following MI, but not 
in those with chronic heart failure. On the other hand, the IM 
method provides the most precise delivery out of all three op-
tions discussed above. However, its major limitation lies in that 
it is classified as highly invasive, therefore critically ill patients 
would be less likely to tolerate this route of administration.
Conclusion
The notion that the human adult heart is a quiescent organ 
incapable of self-regeneration has been successfully challen-
ged over the past decade. It is now evident that the heart 
possesses a significant ability for repair and regeneration. Se-
veral types of stem cells have shown promising potential in 
cardiac muscle regeneration, being it through the delivery of 
extra-cardiac lineages or the activation of endogenous mecha-
nisms. To date, the major stem cell lineages that have lead to 
fruitful findings in animal studies or human clinical trials are 
the C-KIT+ cardiac progenitor cells and the skeletal myoblasts, 
although their limitations cannot be overlooked. Additional in-
vestigations are required in order to elucidate the ideal types 
of stem cells as well as the optimal method for delivery into 
the myocardium. Indeed, the greatest barrier to the applica-
tion of successful stem cell therapy in the future management 
of common cardiovascular diseases, lies within perfecting the 
recruitment, survival and long term engraftment of stem cell 
lineages that possesses promising functional myocardium cha-
racteristics. Moreover, further research is needed to fully com-
prehend the process of endogenous paracrine signaling as well 
as the complex molecular interactions that occur between the 
donor stem cells and the host myocardial tissue.
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Stem Cell Type Suggested Origin Clinical 
Trials
Advantages Disadvantages References
Skeletal myoblasts Mature muscle Phase 1 & 
Phase 2
Wide range of scalability, 
resistant to ischaemia, mul-
tipotency and no teratoma 
formation
Have been associated with cardiac arr-
hythmias and dysynchronous beating
Ref 32-33, 
35-37
Bone marrow 
mononuclear cells
Bone marrow Phase 1 & 
Phase 2
Easy to isolate for implan-
tation
Necessitates more in vivo investigation 
on their nature of cardiovascular diffe-
rentiation
Ref 39-42
Mesenchymal cells Bone marrow & 
adipose tissue
Phase 1 & 
Phase 2
Easy to expand in culture, 
multipotency and less immu-
nogenic than other types of 
stem cells
Wide range of heterogeneity Ref 34, 46, 
47-49
Endothelial progenitor 
cells
Bone marrow & 
peripheral blood
Phase 1 & 
Phase 2
Possess a promising potential 
for neovasculogenesis
Small amounts present in adults with 
cardiovascular disease and related 
comorbidities
Ref 50-55
Embryonic stem cells Inner cell mass of 
pre-implantation 
blastocyst
None Pluripotency Controversial ethical considerations, 
teratoma formation and high possibility 
of Graft VS Host immune reactions
Ref 5
The major types of extra-cardiac stem cells that have gathered significant evidence in favour of repair or regeneration of the myocardium following cardiac 
dysfunction are shown.
Table  2. Summary of Exogenous Stem Cell Populations
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